Targeting neurodegenerative diseases with risuteganib
May 3rd 2021Glenn J. Jaffe, MD, discusses the key points of his virtual presentation on targeting neurodegenerative diseases with risuteganib, minimizing damage to the retina when compromised, and the need for newer treatment therapies to target different pathways.
Read More
Artificial retina engineered from ancient protein now in space
April 14th 2021The National Institute of Health has supported early testing of the artificial retina. Now, scientists are testing whether manufacturing it on the International Space Station results in a viable treatment for people with blinding eye diseases.
Read More
Companies forge collaboration for glaucoma, retinal disease treatment
March 3rd 2021Topcon Corp. will purchase exclusive rights to distribute Iridex Corp.’s retina and glaucoma products, while also acquiring a common equity stake in the company. Iridex will acquire Topcon’s PASCAL product line.
Read More
Investigators receive $10.15 million grant to develop antibody-based dry eye treatment
February 25th 2021With funding from the National Eye Institute, the team of researchers will focus on developing a broad-spectrum immunomodulatory eye drop for patients dealing with dry eye and ocular surface disease stemming from inflammatory and immune system disorders.
Read More
Pitt receives $25 million gift to boost life sciences cluster, advances in vision care
February 25th 2021The bulk of a $25 million gift from the Henry L. Hillman Foundation will drive vision care research and development through The Eye and Ear Foundation and the University of Pittsburgh Departments of Ophthalmology and Otolaryngology.
Read More